Search Technologies
Displaying 1 - 10 of 84 results
Researchers at the University of Maryland have created hundreds of innovations that are available for licensing. Our Discovery Portfolio contains an exciting mix of vaccines, drug targets, therapeutics, devices and cutting edge techniques that promise to make a quantifiable impact on human health and the environment.
Search by keyword:
-
1-THP/LDN (low dose Naltrexone) combination as medication for substance dependence disorder
Published Tuesday, May 27, 2014Addiction is a complex and costly disorder that is difficult to treat due to the effects on multiple brain circuits involved in reward and motivation, learning and memory, and inhibitory control over behavior(s). Treatment options remain limited and addiction to alcohol and illicit drugs cause significant problems and economic burden on society...
Investigator(s): Jia Bei Wang, Sarah Sushchyk
Categories: Therapeutics
Keyword(s): Naltrexone
Docket: JW-2012-106
-
A Method for Monitoring Cancer and for Regulation of Semaphorin 4D to Improve Cancer Immunotherapy Regimens
Published Monday, May 14, 2018The efficacy of current cancer immunotherapies has been limited by the response of immunosuppressive elements such as myeloid derived suppressor cells (MDSC) and T regulatory cells. Understanding the mechanism behind the suppression of antitumor immunity, and finding ways to revert it, should lead to improved cancer immunotherapy outcomes....
Investigator(s): Rania Younis
Categories: Diagnostics, Biomarker, Therapeutics
Keyword(s): Semaphorin 4D, immunotherapy, oncology, head and neck, cancer
Docket: RY-2015-129
-
Analogs of GHB Lacking GABAergic Activity
Published Monday, February 11, 2019The present invention relates to esthers of 3-hydroxyphenyacetic acid and their use to treat narcolepsy and other sleep disorders. Gamma-hydroxybutyric acid (GHB) is a known agonist for the GHB receptor. Unfortunately it also acts at GABA receptors directly and through its metabolization into alpha aminobutyric acid (GABA). As a result,...
Investigator(s): Andrew Coop, Maharaj Ticku, Charles France
Categories: Therapeutics, Small molecules
Keyword(s): narcolepsy, cataplexy, sleep disorderes
Docket: AC-2006-050
-
Anthrax toxin protective antigen proteins engineered to target membrane-anchored serine proteases overexpressed on tumor cells
Published Friday, January 26, 2018Bacillus anthracis is the bacterium that produces the anthrax toxin, which consists of the three distinct proteins protective antigen (PrAg), lethal factor (LF), and edema factor (EF). In order for the toxin to be activated, the PrAg moiety of the toxin must bind to cell-surface proteins and become proteolytically cleaved by the proprotein...
Investigator(s): Toni Antalis, Erik Martin
Categories: Therapeutics, Biologics
Keyword(s): oncology, protein therapy, anthraz, ZMT
Docket: TA-2016-015
-
Antimicrobial Heme Oxygenase Inhibitors and Methods of Use
Published Tuesday, May 27, 2014Antimicrobials are widely used to treat a variety of infections. However, due to overuse and microbial evolution, many antimicrobials are rendered ineffective as first-line therapies. This invention is a new class of broad-spectrum, small-molecule antimicrobials that target the critical enzyme, heme oxygenase that is required to process...
Investigator(s): Angela Wilks, Alexander D. MacKerell, Pedro Lopes, Lena M. Furci
Categories: Therapeutics, Small molecules
Keyword(s): antimicrobial, treatment
Docket: AW-2007-003
-
Attenuated Strains of SalmonellaTyphi as Mucosal Live Typhoid Vaccines and Expression Vectors
Published Tuesday, May 27, 2014Salmonella enterica serovar Typhi is the cause of typhoid fever, which remains an important public health problem in many parts of the world. Attenuated strains of S. Typhi were engineered by researchers at UMB's Center for Vaccine Development, and selected strains have proven safe and immunogenic in Phase 1 and Phase 2 human trials. The same...
Investigator(s): Fernando Noriega, Myron Levine, Marcelo Sztein
Categories: Therapeutics, Vaccines
Keyword(s): vaccine
Docket: FN-98-001
-
Broad spectrum antibacterial therapeutic peptides of probiotic origin
Published Thursday, May 29, 2014Bacterial diarrhea still remains the second leading cause of deaths globally, accounting for one fifth of all deaths among children under five. Small bioactive peptides with both Gram-positive and Gram-negative bactericidal activity have been isolated from Lactobacillus GG. These peptides...
Investigator(s): Alessio Fasano, Ruiliang Lu
Categories: Therapeutics, Biologics
Keyword(s): diarrhea, pathogenic bacteria, peptides, probiotic, Lactobacillus, broad spectrum, biologics
Docket: SF-2006-008
-
Clostridium difficile Type IV Pilin As New Target for Vaccine, Therapeutics and Diagnostics
Published Tuesday, May 27, 2014Type IV pilin proteins are extracellular and easily accessible to the host immune system, as well as being important for initial colonization and biofilm formation. Thus, these proteins present excellent targets for vaccines to prevent pathogen colonization. Neutralizing antibodies directed against pili could lead to...
Investigator(s): Michael Donnenberg
Categories: Diagnostics, Therapeutics, Vaccines
Keyword(s): vaccine
Docket: MD-2008-081
-
Compositions and Methods for Delivering Nucleic Acids to Cells
Published Wednesday, December 6, 2023Summary This invention provides a breakthrough in gene therapy and molecular biology, featuring a non-viral vector system for delivering nucleic acids to cells. It utilizes a polyplex particle with acetylated polyethylenimine (Ac-PEI) and an anionic biomaterial envelope, reducing...
Investigator(s): Ryan Pearson and Atanu Chakraborty
Categories: Therapeutics, Biologics, Methods of Treatment
Docket: RP-2020-012
-
Compositions and Methods for Treating Inflammation and Cancer
Published Thursday, November 2, 2023Summary The patent "Compositions and Methods for Treating Inflammation and Cancer" introduces a novel approach to immunotherapy by modulating the LTβR-NFκB signaling pathways. This technology aims to enhance treatment specificity and efficacy for tissue rejection and certain...
Categories: Therapeutics
Docket: JB-2017-082